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Colistin has long been a reserve drug used for the treatment of carbapenem resistant
Klebsiella pneumoniae. Carbapenem resistance in K. pneumoniae has been increasing
and is as high as 44% in India. Although a reserve agent, with rise in rates of
resistance to carbapenems, the usage of colistin has increased over the years leading to
slow emergence of resistance. Colistin resistance is mainly mediated by the alteration
in the LPS of bacterial outer membrane with the addition of L-Ara4-N and PEtN
molecules. These alterations aremediated bymutations in several genes involved in lipidA
modifications and most commonly mutations inmgrB gene has been reported. Recently
there is emergence of plasmid mediated resistance due to mcr-1 and mcr-2 genes
which poses a threat for the rapid global spread. This study aims at characterizing eight
colistin resistant K. pneumoniae from bacteremia by whole genome sequencing. Eight
K. pneumoniaewere isolated from blood culture during 2013 and 2014 at the Department
of Clinical Microbiology, Christian Medical College, India. Antimicrobial susceptibility
testing was performed and minimum inhibitory concentration (MIC) was determined for
colistin and polymyxin B by broth-micro dilution method. Whole genome sequencing
was performed using Ion Torrent and the genome of all eight isolates was analyzed.
The eight isolates were resistant to all the antimicrobials expect tigecycline. MIC of
colistin and polymyxin B were ranged from 4 to 1024µg/ml and 0.5 to 2048µg/ml
respectively. Multiple mutations were observed in the chromosomal genes involved in
lipid A modifications. mcr-1 and mcr-2 gene was absent in all the isolates. The most
significant were mutations in mgrB gene. Among the eight isolates, four, three and
one were belonged to sequence types ST 231, ST14 and ST147 respectively. Seven
isolates had blaOXA−48 like, one co-expressed blaNDM−1 and blaOXA−48 like genes leading
to carbapenem resistance. Overall, multiple numbers of alterations have been observed.
Pragasam et al. Colistin Resistant K. pneumoniae from India
This includes silent mutations, point mutations, insertions and/or deletions. Mutations in
mgrB gene is responsible for resistance to colistin in this study. Due to emergence of
resistance to reserve drugs, there is a need for combination therapies for carbapenem
resistant K. pneumoniae and colistin must be judiciously used.
Keywords: colistin, polymyxin B, resistance, Klebsiella pneumoniae, whole genome sequencing
INTRODUCTION
Klebsiella pneumoniae is a gram negative bacteria and is a
common cause of severe community and hospital acquired
infections. It readily colonizes humanmucosal surfaces especially
the gastrointestinal (GI) tract and oropharynx (Bagley, 1985; Dao
et al., 2014; Rock et al., 2014). In immunocompromised hosts, it
can invade other sites leading to severe infections (Paczosa and
Mecsas, 2016). In India, carbapenems are commonly used for
treatment of K. pneumoniae due to high rates of ESBL producers
(Ah et al., 2014). Increasing carbapenem resistance has resulted
in colistin (polymyxin E) and tigecycline being used as last
resort drugs for treatment of multidrug resistant (MDR) isolates
(Carmeli et al., 2010).
Polymyxins are cationic polypeptides with five different
compounds, known as polymyxin A–E (Storm et al., 1977).
However, only polymyxin B and polymyxin E (colistin) are
used in clinical practice to treat bacterial infections. When
initially introduced, polymyxins were not widely used due
to their adverse effects of nephrotoxicity and neurotoxicity
(Falagas and Kasiakou, 2006). However, with the rise of
carbapenem resistant organisms, polymyxins have gained
attention as one of the few agents available for treatment
(Falagas et al., 2005). Polymyxins are positively charged
antimicrobial peptide molecules, which act by biding to
negatively charged phosphate groups in the lipidA moiety of
lipopolysaccharides (LPS). This causes disruption and loss of
cell membrane integrity, leading to cell death (Yahav et al.,
2012).
Due to its rising and sometimes inappropriate use, colistin
resistance is increasing. Resistance to colistin is mainly mediated
by modification of the LPS moiety with the addition of positively
charged L-Ara4-N and PEtN molecules (Falagas et al., 2010).
This modification decreases the negative charge of the outer
membrane, reducing its interaction with colistin (Velkov et al.,
2013). It is mainly due to mutations in the two component
regulatory systems. The most common mutations are in mgrB,
phoP/phoQ, pmrA, pmrB, pmrC, and crrABC (Cheng et al., 2010;
Poirel et al., 2015; Wright et al., 2015).
Recently, plasmid mediated colistin resistance named
mcr-1 (plasmid Mediated Colistin Resistance) encoding
for phosphoethanolamine transferase has been reported in
Escherichia coli and K. pneumoniae from China (Liu et al., 2016).
Following this,mcr-1.2, a variant ofmcr-1, was identified in KPC
producing K. pneumoniae in Italy (Di Pilato et al., 2016) followed
by themcr-2 gene reported from Belgium, This had 76% identity
with themcr-1 gene previously reported (Xavier et al., 2016). The
increasing number of resistance mechanisms reported in such a
short time period is alarming.
The emergence of colistin resistance is a serious cause for
concern for both clinicians and patients, particularly in countries
with high rates of carbapenem resistant Enterobacteriaceae
such as China, India, and Greece. Hence, it is necessary to
perform surveillance studies for colistin resistance organisms
in Indian hospitals. In this study, we report eight colistin
resistant K. pneumoniae isolated from bloodstream infections
from Christian Medical College, Vellore, India. Whole genome
sequencing was employed to study the mechanisms of colistin
resistance such as chromosomal genes and plasmid mediated
mcr-1 andmcr-2 genes.
MATERIALS AND METHODS
Bacterial Strains
A total of eight clinical isolates of colistin resistant (CR)
K. pneumoniae (CRKP1–CRKP8) were included in this study.
These CR-K. pneumoniae were isolated in blood culture from
patients admitted at Christian Medical College, Vellore, South
India between 2013 and 2015. All the eight isolates were identified
up-to species level as per standard biochemical tests (Versalovic
et al., 2011) and by Vitek2 (bioMerieux)
Demographic and Clinical Details of
Patients
These were obtained from electronic medical records available in
the hospital intranet.
Antimicrobial Susceptibility Testing
The Kirby Bauer disk diffusion method was performed to
ascertain antimicrobial susceptibility to commonly used agents.
This included ceftazidime (30 µg), cefotaxime (30 µg), cefoxitin
(30 µg), cefepime (30 µg), piperacillin/tazobactam (100/10
µg), imipenem (10 µg), meropenem (10 µg), ciprofloxacin
(5 µg), gentamicin (10 µg), netilmicin (30 µg), amikacin (30
µg), polymyxin B (300 units), and tigecycline (15 µg). The
susceptibility results were interpreted as per CLSI (2013, 2014,
2015) guidelines, respectively (CLSI M100S-23; CLSI M100S-24;
CLSI M100S-25). Tigecycline results were interpreted according
to FDA criteria (http://www.accessdata.fda.gov/drugsatfda_docs/
label/2009/021821s016lbl.pdf).
The minimum inhibitory concentration (MICs) were
determined by broth micro dilution method (BMD) for both
polymyxin agents, colistin and polymyxin B. The results were
interpreted as per EUCAST guidelines (EUCAST, 2013, 2014,
2015, respectively), (EUCAST susceptibility breakpoint v 3.0,
v 4.0 and v 5.0). E. coli ATCC 25922 was used as a quality control.
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Carbapenemase Detection by CarbaNP
and Multiplex PCR
The CarbaNP test was performed for all isolates by the previously
described method (Nordmann et al., 2012). K. pneumoniae
ATCC BAA 1705 and K. pneumoniaeATCC BAA 1706 were used
as positive and negative controls, respectively.
For molecular testing, all the isolates were grown overnight
on blood agar and DNA was extracted using Qiagen kit
as per manufacturer’s protocol (Qiagen Bacterial DNA mini
kit). The presence of carbapenemase genes such as blaSPM,
blaIMP, blaVIM, blaNDM, blaKPC, and blaOXA−48 like genes
were determined by conventional multiplex PCR as described
previously (Anandan et al., 2015). The products were analyzed
on 2% agarose gel stained with ethidium bromide. Respective
positive controls were used for each run (Courtesy: IHMA,
Inc., USA).
Molecular Characterization of Colistin
Resistance
PCR and Sequencing for LPS Modifications Genes
Genes involved in LPS modification includingmgrB, phoP/phoQ,
and pmrA/pmrB/pmrD were amplified and sequenced as
previously described (Jayol et al., 2015; Wright et al., 2015).
Whole Genome Sequencing (WGS) for
CR- K. pneumoniae
WGS was performed using the Ion Torrent PGM platform
using 400 bp read chemistry. Sequencing was performed as per
the protocol recommended by Life Technologies. Raw reads
were assembled de novo using Assembler SPAdes software
v4.4.0.1 in Torrent suite server version 4.4.3. The genome
was annotated using the PATRIC (Pathosystems Resource
Integration Center -https://www.patricbrc.org) and RAST
(Rapid Annotations using Subsystems Technology) databases.
Upon annotation, antimicrobial resistance genes were found as
per ARDB and CARD, respectively. These genes were further
taken for mutational analysis. The whole genome sequences
were deposited at GenBank under the following accession
numbers: CRKP1 (MOXM00000000); CRKP2 (MIEJ00000000);
CRKP3 (MPCT00000000); CRKP4 (MDZG00000000);
TABLE 1 | Minimum inhibitory concentration (MIC) for colistin and
polymyxin B by broth micro dilution (BMD) for K. pneumoniae.
MICRO No. MIC (BMD)
Colistin
(µg/ml)
Polymyxin
B (µg/ml)
CRKP1 4 0.5
CRKP2 8 32
CRKP3 8 64
CRKP4 16 64
CRKP5 16 64
CRKP6 16 64
CRKP7 16 64
CRKP8 1024 2048
CRKP5 (MOXL00000000); CRKP6 (MEBR00000000); CRKP7
(MOXN00000000); CRKP8 (LZYN00000000).
Molecular Typing of CR K. pneumoniae by MLST
The MLST database at the Center of Genomic Epidemiology was
used to identify the sequence types (ST) of the study isolates using
WGS data (https://cge.cbs.dtu.dk/services/MLST/).
eBURST
The program eBURST v 3.0 was used to identify clonal
complexes.
RESULTS
Demographic and Clinical Details of
Patients
The demographic and clinical details of each patient were
obtained from electronic medical records. The patients’ ranged
from 25 to 59 years in age. Five were male. Six patients were
under the care of the hematology team, one was under the
care of neurology, and one under nephrology. All but one
patient was immunocompromised. K. pneumoniae sepsis was
hospital acquired in all cases and the sources of infection were
neutropenic sepsis (n = 4), pneumonia (n = 1), urosepsis
(n = 1), intra-abdominal infection (n = 1), and line infection
(n = 1). Meropenem was administered to all patients before K.
pneumoniae was isolated and colistin was administered to five
patients. Four patients expired within 30 days of infection and
seven within 90 days of infection.
Antimicrobial Susceptibility Testing
All isolates were extremely drug resistant (XDR) as per
the definition of Magiorakos et al. (2012) All isolates were
resistant to cephalosporins, carbapenems, fluoroquinolones,
aminoglycosides, and polymyxin B by disk diffusion
but were susceptible to tigecycline. The MIC-values
determined by BMD for colistin and polymyxin B ranged
from 4 to 1024 and 0.5 to 2048 µg/ml, respectively.
The MIC results of the eight isolates are summarized in
Table 1.
Carbapenemase Detection
CarbaNP test was positive for all the eight isolates tested
indicating the production of carbapenemases. Multiplex
PCR for carbapenamase genes revealed the presence of
blaOXA−48 like gene in seven isolates. One isolate co-expressed
blaNDM−1 + OXA−232 genes.
Whole Genome Sequence Analysis
For whole genome sequencing analysis, PATRIC, and RAST
databases have been used to analyse the annotated sequences
(http://patricbrc.org/) (http://rast.nmpdr.org/). As these eight
isolates were XDR strains, multiple resistance genes against
various classes of antimicrobial agents have been identified.
These are summarized in Table 2. For cephalosporin resistance,
the most common resistance genes were blaTEM, blaSHV, and
blaCTX−M−15. For carbapenem resistance, blaOXA−232, a variant
of blaOXA−48 like gene was found in six of the study isolates, one
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isolate co-producing blaOXA−232 and blaNDM−1, while one isolate
had blaOXA−181, also a variant of the blaOXA−48 like gene.
For colistin resistance, RAST classified 11 genes involved in
lipid Amodification with L-Ara4N pathway. These included ugd,
arnA_DH, arnA_FT, arnB, arnC, arnT, pmrJ, pmrL, pmrD, pmrM,
and pmrG. In addition, 10 genes were classified under genes
involved in Lipid Amodifications. These include pagP,pagL, lpxO,
phoQ, phoP, pmrA, pmrB, eptA, eptB, and yijP. Of these 21 genes,
a few gene sequences could not be retrieved from the annotated
genomes of the study isolates from RAST/PATRIC databases and
hence analysis was not done. However, for the available genes,
sequences were retrieved and analyzed for mutations. Upon
analysis, multiple mutations were observed in various genes. In
seven isolates, there was a change from arginine to alanine at
position 114 of phoP. In one isolate, there was a change from
arginine to alanine in position 128. In phoQ, five isolates had
a substitution of glycine for aspartic acid at position 146 and
three isolates had the same substitution at position 150. The
mutations in other genes such as pmrB, pmrC, phoB, arnB, arnC,
arnT, arnA_FT, and pagP are listed in Table 3 and have not been
reported in other studies to date. No mutations were found in
pmrA, eptB, and phoR genes in any of the isolates analyzed.mcr-1
andmcr-2 genes were absent in all the study isolates.
Targeted Gene Sequencing Analysis of
Mutations in Genes Involved in LPS
Modifications
Of the eight isolates screened for mutations, CRKP3 and CRKP6
had a premature stop codon inmgrB gene resulting in a truncated
protein of 27 amino acids. Whereas, a frame shift mutation
in CRKP4 and deletion of nucleotide A at 10th position of
mgrB gene in CRKP7 was noted, this could be responsible for
the resistant phenotype. Three isolates, CRKP1, CRKP2, and
CRKP5 did not have anymutations in themgrB gene. Sequencing
of two component systems phoP/phoQ and pmrA/pmrB and
pmrD foundmultiple silent mutations. Since targeted sequencing
results did not reveal much information, WGS data analysis
was performed to further understand the additional resistance
mechanisms.
Molecular Typing of CR K. pneumoniae by
MLST
MLST database available at https://cge.cbs.dtu.dk/services/
MLST/ by the Center of Genomic Epidemiology was used to
identify the sequence type (ST) of the study isolates using WGS
data. Of the eight CR-K. pneumoniae, three different sequence
types were identified (ST231, ST14, and ST147). Four isolates
belonged to ST231 (CRKP3, CRKP4, CRKP6, and CRKP7),
three to ST14 (CRKP1, CRKP2, and CRKP5) and one to ST147
(CRKP8).
eBURST
eBURST analysis found no clustering of colistin resistant isolates
into a clonal complex. The result is depicted in Figure 1.
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FIGURE 1 | eBURST analysis of colistin resistant K. pneumoniae.
DISCUSSION
Antimicrobial resistance is on the rise globally. The limited
treatment options available for carbapenem resistant K.
pneumoniae have resulted in increasing use of colistin, despite
its adverse effects. Colistin resistance is now emerging, leaving
clinicians with very few options to treat these extensively drug
resistant bacteria.
The main challenge in screening colistin resistance lies in
determining polymyxin susceptibility (Balaji et al., 2011).
Polymyxins are large cationic peptide molecules. They
do not diffuse through agar well, hence disk diffusion is
neither reliable nor recommended. A reliable screening test
is awaited. Other susceptibility methods produce variable
and discrepant results. Further, polymyxin B and colistin
produce discrepant results (Hindler and Humphries, 2013;
Humphries, 2015). Colistin susceptibility testing by disk
diffusion has resulted in very major errors of up to 32%
when compared with broth or agar dilution methods for
colistin (Tan and Ng, 2006; van der Heijden et al., 2007).
E-test may also produce discrepant results, hence broth
microdilution is considered the reference method (Tan et al.,
2007).
From this study results, the MIC was found to be two to
eight fold higher for polymyxin B when compared to colistin by
BMD method. Such discordant results could be due to the non-
reliability of MIC testing for polymyxin B. These findings concur
with previous studies where the MIC was found to be higher for
polymyxin B than colistin (van der Heijden et al., 2007).
A number of studies have reported discrepant results when
testing polymyxin B and colistin susceptibility by disk diffusion
andMICmethods (Behera et al., 2010). Similar observations were
noted in this study; all eight CR-K. pneumoniae were found to be
resistant on BMD testing with variable MIC values for polymyxin
B and colistin as shown in Table 1. Detection of molecular
resistance mechanisms are based on preliminary screening with
polymyxins. This emphasizes the need for a reliable screening
test.
mgrB is the commonest chromosomal gene mutation
involving modification of LPS which includes insertional
inactivation causing colistin resistance. The second commonest
cause is multiple mutations in the pmrAB and phoPQ, the two
component systems involved in the LPS modifications.
Of the genes analyzed, mutations in mgrB with truncation
to 27 amino acids concurs with previous studies (Poirel et al.,
2015). The T157P mutation in pmrB has also been previously
identified (Jayol et al., 2014, 2015; Olaitan et al., 2014). Multiple
new mutations were identified in various genes in this study.
These include mutations in phoP (R114A), phoQ (D146G), pmrB
(L334P, A246T), pmrC (V39L, R152H, A279G, D477N, D480N,
S260L, C27F, V50L, A235P), phoR (R69C), arnB (A112D, D285E,
G47D, I126V), arnC (S30T), arnA_FT (I260L, N442K, L161C,
S18A, T185A), and pagP (F170I). However, the significance of
these mutations and their contribution to colistin resistance
needs to be studied further.
One isolate (CRKP8) had very high MICs of 1024 µg/ml and
2048µg/ml by BMD for colistin and polymyxin B respectively.
This is a huge variation in MIC between two different
methodologies.
The clonality distribution of colistin resistant K. pneumoniae
is of great interest. Worldwide, sequence types (ST) associated
with colistin resistant K. pneumoniae are ST258, ST512, and
ST147 (Mammina et al., 2012; Cannatelli et al., 2014). However,
in our study it was ST231, ST14 and ST147. Our study agrees
with Jayol et al who reported ST14 K. pneumoniae producing
blaOXA−48 like (Jayol et al., 2014, 2015). However, in this study,
the resistance mechanisms were mgrB mediated rather than due
to mutation in pmrB. One of the study isolates belonging to
ST14 (CRKP6) was a blaNDM−1 producer. Isolates with mutated
and/or truncated mgrB were of different sequence types. This
further indicates that resistance determinants are irrespective of
the sequence types.
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Interestingly, isolates CRKP3 and CRKP6, both of which had a
mutation inmgrB gene resulting in a truncated product, were not
of the same clone. However, isolate CRKP4 and CRKP7 which
had a frame shift mutation inmgrB gene, both belonged to ST231.
CONCLUSION
Inappropriate usage of colistin in the clinical setting should
be avoided, as selection pressure may contribute to colistin
resistance due tomutations. Further, use of colistin in agricultural
practices should be forbidden to prevent the further spread
of resistance. The global demand for colistin in agriculture is
estimated to reach 16,500 tons by 2021 (QYResearch Medical
Research Centre, 2015). India is also one of the leading producers
of colistin for veterinary use (Liu et al., 2016). In this study,
multiple mutations in the genes coding for LPSmodification have
been observed. These include silent mutations, point mutations,
insertions, and/or deletions. Mutation profiles were observed
to be divergent. This signifies the fact that clinical isolates do
develop mutations for survival. Altogether, mutations in the
mgrB gene were found to be the most common, followed by
mutations in the other genes such as pmrB, pmrC, arnB, and
arnAFT. This observation emphasizes that colistin resistance is
multifactorial. However, the significant effect of these mutations
observed in this study needs to be validated. Therefore, further
studies should be focused on the role of these genes in
pathways involving LPS modifications conferring resistance to
colistin.
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